Choriogonadotropin Alfa

Choriogonadotropin alfa (Ovidrel) is a real, FDA-approved recombinant version of hCG, used to trigger final egg maturation in IVF — mechanistically identical to the native/urinary hCG already covered on this site, with manufacturing consistency as the actual point of difference.

The same hormone, made differently

Choriogonadotropin alfa is recombinant human chorionic gonadotropin (hCG) — the same hormone this site already covers in its native/urinary form on the HCG page, produced in CHO cells rather than purified from the urine of pregnant women. It binds the same LH/hCG receptor to trigger final oocyte maturation and ovulation timing in an IVF cycle. This is a case where the mechanism is genuinely identical between the two forms — the entire rationale for the recombinant version is manufacturing consistency, not a different biological effect.

The approval and pivotal trials

The FDA approved choriogonadotropin alfa (as Ovidrel) on 20 September 2000. A US registration trial randomized 297 women across 20 fertility centers to two doses of recombinant hCG or standard urinary hCG, finding equivalent oocyte yields across all three arms — establishing the recombinant product as clinically interchangeable with urinary hCG at the appropriate dose, not superior or inferior. A 2016 Cochrane review (Youssef et al., PMID 27106604) specifically examined recombinant versus urinary hCG for oocyte-maturation triggering across multiple trials — a rigorous, appropriately skeptical source worth reading directly for the exact comparative figures before citing a specific effect size.

Current status

Still actively marketed; not discontinued. No grey-market or wellness-adjacent presence — prescription-only, used specifically within a monitored IVF cycle.